Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Home
>
Premium Biotech Coverage
>
Current News
Current News
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Amplia Therapeutics (ATX)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
EBR Systems (EBR)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Patrys (PAB)
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
January 4th, 2024
Top Six Picks for 2024 (Dimerix; ASX = DXB)
Read More
January 4th, 2024
Impressive Results from Neuren's NNZ-2591 Phase II Clinical Trial in Phelan- McDermid Syndrome
Read More
December 12th, 2023
Investor Interest Starts Return to Biotech Sector (Clinuvel)
Read More
December 12th, 2023
Investor Interest Starts Return to Biotech Sector (Dimerix)
Read More
December 12th, 2023
Investor Interest Starts Return to Biotech Sector (Imugene)
Read More
December 12th, 2023
Investor Interest Starts Return to Biotech Sector (Neuren)
Read More
November 20th, 2023
Neuren Completes First of Four Phase II Studies
Read More
November 20th, 2023
Adalta Finalises Data for Licensing with Lead Compound AD214
Read More
November 20th, 2023
Clinuvel Pharmaceuticals - Core Growth Focus Ahead
Read More
November 20th, 2023
First Results for Imugene's Oncolytic Virus CF33
Read More
Pages
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
